Vortioxetine - Lundbeck

Drug Profile

Vortioxetine - Lundbeck

Alternative Names: Brintellix®; LU-AA21004; LuAA 21004; Trintellix

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Takeda
  • Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfides
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists; Serotonin 1D receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 7 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Anxiety disorders
  • No development reported Generalised anxiety disorder
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 04 Dec 2017 Registered for Major depressive disorder in China (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Generalised-anxiety-disorder(In volunteers) in China (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in United Kingdom (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top